Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who has histologically confirmed and newly diagnosed breast cancer~* Patient who has clinical stage I, II, or IIIa operable breast cancer according to AJCC (American Joint Committee on Cancer) Breast Cancer Staging 7th edition~* Patient who has HER2-positive status confirmed locally, defined as 3+ score by IHC (immuno-histochemistry).~Exclusion Criteria:~* Patient who has bilateral breast cancer~* Patient who has received prior treatment for breast cancer, including chemotherapy, biologic therapy, hormone therapy, immunotherapy, radiation or surgery, including any prior therapy with anthracyclines.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P6 (Type: EXPERIMENTAL): None
- Trastuzumab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).